A. Sinclair Dunlop Sells 37,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at $3,623,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

A. Sinclair Dunlop also recently made the following trade(s):

• On Friday, June 21st, A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $35.63 on Thursday. The company has a market cap of $4.32 billion, a PE ratio of -10.30 and a beta of 0.88. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals, Inc. has a 52 week low of $33.49 and a 52 week high of $73.80. The business has a 50 day moving average price of $38.05 and a 200-day moving average price of $44.06.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. During the same period last year, the business earned ($1.02) EPS. The business’s revenue was up 110.2% on a year-over-year basis. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. Teachers Retirement System of The State of Kentucky bought a new position in shares of Apellis Pharmaceuticals during the 2nd quarter worth approximately $725,000. Algert Global LLC lifted its holdings in Apellis Pharmaceuticals by 137.8% during the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after acquiring an additional 71,650 shares during the period. AQR Capital Management LLC lifted its holdings in Apellis Pharmaceuticals by 337.3% during the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after acquiring an additional 190,420 shares during the period. Toronto Dominion Bank boosted its position in Apellis Pharmaceuticals by 146.0% in the second quarter. Toronto Dominion Bank now owns 24,600 shares of the company’s stock worth $944,000 after purchasing an additional 14,601 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Apellis Pharmaceuticals in the 2nd quarter valued at $2,350,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

APLS has been the subject of a number of research analyst reports. Robert W. Baird lifted their target price on Apellis Pharmaceuticals from $86.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Wedbush boosted their target price on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. The Goldman Sachs Group increased their target price on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Finally, Piper Sandler started coverage on shares of Apellis Pharmaceuticals in a research report on Friday, May 31st. They set a “neutral” rating and a $46.00 price objective on the stock. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $71.67.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).